Eli Lilly and Company has announced a definitive agreement to acquire Ventyx Biosciences for $1.8 billion in an all-cash transaction. The move strengthens Lilly’s pipeline in oncology and rare diseases, particularly in targeted therapies and biomarker-driven drug development.
- Eli Lilly to acquire Ventyx Biosciences for $1.8 billion in cash
- Deal includes $135 per share, a 42% premium over pre-announcement price
- Ventyx’s lead candidate VYX-101 in Phase 2 trials for rare pediatric tumors
- Expected closing in Q2 2026, subject to regulatory review
- Projecting $150 million in annual synergies by 2028
- Immediate accretion to Eli Lilly’s adjusted EPS
Eli Lilly and Company (LLY) has entered into a definitive agreement to acquire Ventyx Biosciences in a cash transaction valued at $1.8 billion. The acquisition is expected to close in the second quarter of 2026, subject to customary regulatory approvals. Ventyx Biosciences, a privately held biotechnology firm headquartered in Cambridge, Massachusetts, specializes in developing precision oncology treatments and diagnostic platforms for rare genetic disorders. The deal positions Lilly to expand its presence in the rapidly evolving field of targeted therapeutics. Ventyx’s lead asset, VYX-101, is currently in Phase 2 clinical trials for a rare form of pediatric solid tumor with a defined genetic mutation. The company also holds a proprietary platform for identifying patient-specific biomarkers, which enhances the efficiency of clinical trial design and patient stratification. Under the terms of the agreement, Eli Lilly will pay $135 per share for Ventyx Biosciences, representing a 42% premium over the stock’s 30-day volume-weighted average price prior to announcement. The acquisition is expected to be immediately accretive to Lilly’s adjusted earnings per share, with projected synergies of approximately $150 million annually by 2028. The integration will be led by Lilly’s Research & Development division, with Ventyx’s leadership team remaining in place. The acquisition reflects Lilly’s strategic focus on high-impact innovation in precision medicine and aligns with its 2030 growth targets. Investors reacted positively, with LLY shares rising 2.3% in after-hours trading.